Corimmun
| Invested since | 2006 |
| Based in | Bavaria |
About the company
Corimmun is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative peptide and biological drugs in indications with unmet medical needs.
Exit since June 2012.
More startups from Life Sciences
Exit
GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with …
To the complete profileof GQ Bio Therapeutics
Exit
RIMASYS offers prefractures specimen for educational purposes in the field of orthopedic surgery. The innovative MedTech company is setting new standards in surgical education and implant development through innovative education …
To the complete profileof RIMASYS
PreComb Therapeutics AG is a privately held Swiss biotech company founded in 2018 by Jens M. Kelm, Peter Steiner and Olivier Mauti with the aim of developing technologies that bring …
To the complete profileof PreComb
neotiv is a spin-off of the Otto von Guericke University in the German city of Magdeburg in close collaboration with the Magdeburg site of the German Centre for Neurodegenerative Diseases …
To the complete profileof neotiv
TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the …
To the complete profileof TolerogenixX
Biograil is a Danish start-up using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device …
To the complete profileof Biograil